Unicycive Therapeutics (UNCY) News Today $0.61 0.00 (-0.51%) As of 12:28 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Unicycive Therapeutics' (UNCY) Buy Rating Reiterated at HC WainwrightApril 14 at 1:45 AM | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Unicycive Therapeutics (NASDAQ:UNCY)HC Wainwright reiterated a "buy" rating and issued a $7.50 price objective on shares of Unicycive Therapeutics in a report on Friday.April 13 at 8:17 AM | marketbeat.comUnicycive presents new patient-level data from Phase 2 study of OLCApril 12 at 12:01 AM | markets.businessinsider.comResearch Analysts Offer Predictions for UNCY FY2025 EarningsUnicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Analysts at Brookline Capital Management raised their FY2025 EPS estimates for shares of Unicycive Therapeutics in a research note issued to investors on Tuesday, April 1st. Brookline Capital Management analyst K. Raja now expects that thApril 6, 2025 | marketbeat.comHC Wainwright Analysts Reduce Earnings Estimates for UNCYUnicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - HC Wainwright dropped their Q1 2025 earnings estimates for shares of Unicycive Therapeutics in a report released on Tuesday, April 1st. HC Wainwright analyst E. Arce now anticipates that the company will post earnings of ($0.08) per shareApril 6, 2025 | marketbeat.comUNCY FY2025 EPS Boosted by Brookline Capital ManagementApril 6, 2025 | americanbankingnews.comBrookline Capital Management Estimates UNCY Q1 EarningsUnicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities researchers at Brookline Capital Management issued their Q1 2025 earnings per share (EPS) estimates for shares of Unicycive Therapeutics in a note issued to investors on Tuesday, April 1st. Brookline Capital Management analyst K.April 5, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for UNCY Q1 Earnings?April 5, 2025 | americanbankingnews.comUnicycive Therapeutics price target raised to $7.50 from $4 at H.C. WainwrightApril 2, 2025 | markets.businessinsider.comNoble Financial Sticks to Their Buy Rating for Unicycive Therapeutics (UNCY)April 2, 2025 | markets.businessinsider.comHC Wainwright Increases Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $7.50HC Wainwright increased their price target on Unicycive Therapeutics from $4.00 to $7.50 and gave the company a "buy" rating in a research report on Tuesday.April 2, 2025 | marketbeat.comUnicycive Therapeutics (NASDAQ:UNCY) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPSUnicycive Therapeutics (NASDAQ:UNCY - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.13).April 1, 2025 | marketbeat.comUnicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | globenewswire.comUnicycive Therapeutics reports FY24 EPS (56c), consensus (51c)April 1, 2025 | markets.businessinsider.comUnicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business UpdateMarch 31, 2025 | globenewswire.comUnicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on ThursdayUnicycive Therapeutics (NASDAQ:UNCY) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest UpdateUnicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 1,400,000 shares, a growth of 76.1% from the February 13th total of 795,200 shares. Approximately 1.6% of the company's shares are short sold. Based on an average daily trading volume, of 1,090,000 shares, the short-interest ratio is presently 1.3 days.March 15, 2025 | marketbeat.comUnicycive to present patient reported outcomes data from UNI-OLC-201 studyMarch 13, 2025 | markets.businessinsider.comUnicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of HyperphosphatemiaMarch 13, 2025 | globenewswire.comUnicycive Therapeutics (NASDAQ:UNCY) Trading Down 2% - Should You Sell?Unicycive Therapeutics (NASDAQ:UNCY) Shares Down 2% - Here's What HappenedMarch 8, 2025 | marketbeat.comUnicycive Therapeutics’ OLC shows synergy with tenapanor in published studyFebruary 21, 2025 | markets.businessinsider.comUnicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360February 20, 2025 | globenewswire.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Large Growth in Short InterestUnicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 1,240,000 shares, a growth of 25.4% from the December 31st total of 989,200 shares. Currently, 1.4% of the company's shares are sold short. Based on an average daily volume of 1,550,000 shares, the short-interest ratio is currently 0.8 days.January 31, 2025 | marketbeat.comBuy Rating for Unicycive Therapeutics Driven by Promising OLC Treatment and Reduced Pill BurdenJanuary 29, 2025 | markets.businessinsider.comUnicycive Therapeutics' (UNCY) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $4.00 price objective on shares of Unicycive Therapeutics in a research note on Wednesday.January 29, 2025 | marketbeat.comUnicycive highlights challenges in phosphate managementJanuary 28, 2025 | msn.comUnicycive announces publication of patient perspectives on phosphate managementJanuary 28, 2025 | markets.businessinsider.comHere's Why We're Watching Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn SituationJanuary 28, 2025 | finance.yahoo.comUnicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological ScienceJanuary 28, 2025 | globenewswire.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Up 25.4% in DecemberUnicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 1,240,000 shares, a growth of 25.4% from the December 15th total of 989,200 shares. Currently, 1.4% of the company's shares are short sold. Based on an average daily volume of 1,550,000 shares, the short-interest ratio is currently 0.8 days.January 16, 2025 | marketbeat.comPositive Buy Recommendation for Unicycive Therapeutics Driven by Promising Trial Results and Revenue ForecastsJanuary 9, 2025 | markets.businessinsider.comUnicycive Therapeutics (NASDAQ:UNCY) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $4.00 price objective on shares of Unicycive Therapeutics in a report on Wednesday.January 8, 2025 | marketbeat.comUnicycive Therapeutics announces publication of OLC dose escalation dataJanuary 8, 2025 | markets.businessinsider.comUnicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational ScienceJanuary 7, 2025 | globenewswire.comUnicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical TherapeuticsDecember 17, 2024 | markets.businessinsider.comShort Interest in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Drops By 33.6%Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 837,200 shares, a drop of 33.6% from the November 15th total of 1,260,000 shares. Based on an average daily trading volume, of 1,610,000 shares, the days-to-cover ratio is presently 0.5 days. Currently, 1.0% of the company's stock are sold short.December 13, 2024 | marketbeat.comWalleye Capital LLC Invests $2.04 Million in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)Walleye Capital LLC acquired a new position in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 5,000,000 shares of the company's stock, vDecember 4, 2024 | marketbeat.comBreakeven On The Horizon For Unicycive Therapeutics, Inc. (NASDAQ:UNCY)November 28, 2024 | uk.finance.yahoo.comAcuta Capital Partners LLC Purchases Shares of 1,979,199 Unicycive Therapeutics, Inc. (NASDAQ:UNCY)Acuta Capital Partners LLC acquired a new position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm acquired 1,979,199 shares of the company's stock, valued at approximately $807,000. Unicycive TherapeutNovember 28, 2024 | marketbeat.comGreat Point Partners LLC Buys Shares of 8,559,000 Unicycive Therapeutics, Inc. (NASDAQ:UNCY)Great Point Partners LLC bought a new stake in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 8,559,000 shares of the company's stock, valued at approximately $3,491,0November 27, 2024 | marketbeat.comBenchmark Reiterates Speculative Buy Rating for Unicycive Therapeutics (NASDAQ:UNCY)Benchmark reiterated a "speculative buy" rating and set a $3.00 price objective on shares of Unicycive Therapeutics in a research report on Friday.November 22, 2024 | marketbeat.comUnicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare ConferenceNovember 21, 2024 | globenewswire.comUnicycive Therapeutics price target raised to $4 from $2.50 at H.C. WainwrightNovember 15, 2024 | markets.businessinsider.comUnicycive Therapeutics (UNCY) Gets a Buy from Noble FinancialNovember 15, 2024 | markets.businessinsider.comUnicycive Therapeutics expects cash to fund operations into 2026November 14, 2024 | markets.businessinsider.comUnicycive Announces Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | globenewswire.comUnicycive Therapeutics announces U.S. FDA acceptane for NDA for OLCNovember 13, 2024 | markets.businessinsider.comPositive Buy Rating for Unicycive Therapeutics Driven by NDA Acceptance and Strong Market Potential for Oxylanthanum CarbonateNovember 13, 2024 | markets.businessinsider.comUnicycive: FDA to Review Lead Drug Candidate for HyperphosphatemiaNovember 11, 2024 | marketwatch.comUnicycive Says FDA Accepts NDA For Oxylanthanum Carbonate To Treat Patients With CKD On DialysisNovember 11, 2024 | markets.businessinsider.com Remove Ads Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address UNCY Media Mentions By Week UNCY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UNCY News Sentiment▼0.490.80▲Average Medical News Sentiment UNCY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UNCY Articles This Week▼51▲UNCY Articles Average Week Remove Ads Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Olema Pharmaceuticals News Compass Therapeutics News Immutep News Bright Minds Biosciences News Foghorn Therapeutics News MBX Biosciences News iTeos Therapeutics News Corvus Pharmaceuticals News Checkpoint Therapeutics News Y-mAbs Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:UNCY) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy UNCY Stock Free UNCY Stock Alerts